NEXI: רווח נקי למניה (EPS TTM) NexImmune Corp

NexImmune, Inc. (NEXI) is mitigating risks through a diversified portfolio of tumor-fighting research. However, geopolitical strife and sanctions could potentially delay material supplies and testing. The company's annual revenue per share on the GURU.Markets chart has stabilized at -24.31. The immunotherapy sector relies on its own development cycle, transforming such assets into a reliable hedge against macroeconomic shocks.

This indicator determines the portion of net income attributable to a single common share. The trailing twelve-month net income per share trend allows for the tracking of capital generation efficiency. The metric is calculated as the ratio of total income over four quarters to the total number of securities. It bridges the gap between GAAP and Non-GAAP standards. For NexImmune, Inc. (NEXI), this figure reflects the consequences of a strategic shift toward patent monetization and cost reduction.